CMS Rejects Medicare Payment for Genetic-Based Warfarin Dosing

CMS has decided against paying for genetic tests to help guide warfarin dosing for Medicare recipients, saying that "available evidence does not demonstrate that pharmacogenomic testing to predict warfarin responsiveness improves health outcomes in Medicare beneficiaries."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.